Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma [Phase 2]
Phase 2 trial of Velcade (bortezomib) plus Rituximab for follicular non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-02-28Clinical Trial Update: Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma [Phase 3]
A Phase 3 trial evaluating interleukin-2 versus observation after standard therapy in adults with recurrent non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS trial_result · 2013-02-27Clinical Trial Update: Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating chemotherapy with or without monoclonal antibody therapy for stage III or stage IV low-grade follicular lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2013-02-21Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL [NA]
The study evaluated a Rituximab, Cyclophosphamide, Bortezomib, and Prednisone regimen in patients with stage III/IV follicular lymphoma or m…
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia [NA]
A clinical trial evaluated arsenic trioxide in patients with relapsed or refractory lymphoma and leukemia; the study status is terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas [Phase 1]
Phase 1 clinical trial evaluating 17-DMAG (alvespimycin), an HSP90 inhibitor, in patients with metastatic or unresectable solid tumors or ly…
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma [Phase 1]
An update on a Phase 1 trial of oblimersen in combination with gemcitabine for patients with advanced solid tumors or lymphoma, which has be…
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating interferon alfa plus thalidomide in relapsed or refractory non-Hodgkin lymphoma, specifically recurrent follicula…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial update for cilengitide in patients with advanced solid tumors or lymphoma, with the study status reported as completed.
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma [Phase 1]
A Phase 1 trial evaluating genetic testing-guided irinotecan therapy in patients with solid tumors or lymphoma; the study status is complete…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial update evaluating oblimersen with rituximab and combination chemotherapy in relapsed or refractory aggressi…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study evaluated oxaliplatin in patients with relapsed or refractory non-Hodgkin lymphoma across multiple subtypes and has complete…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma [Phase 2]
A Phase 2 trial investigating 506U78 in patients with recurrent or refractory non-Hodgkin's lymphoma and T-cell lymphomas was terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-14Clinical Trial Update: SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial of SB-715992 in patients with metastatic or unresectable solid tumors and various Hodgkin's and non-Hodgkin's lymphomas has be…
-
CLINICAL_TRIALS trial_result · 2013-01-11Clinical Trial Update: Bryostatin and Vincristine in B-Cell Malignancies [Phase 1]
Phase 1 trial evaluating Bryostatin-1 in combination with Vincristine in several recurrent or refractory B-cell malignancies; the study has …
-
CLINICAL_TRIALS trial_result · 2013-01-10Clinical Trial Update: Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation [Phase 2]
A Phase 2 clinical trial evaluating Bryostatin-1 in combination with vincristine for progressive or relapsed non-Hodgkin lymphoma after bone…
-
CLINICAL_TRIALS trial_result · 2013-01-10Clinical Trial Update: Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial evaluating the combination of gossypol, paclitaxel, and carboplatin in patients with metastatic or unresectable solid tumors, …
-
CLINICAL_TRIALS trial_result · 2013-01-07Clinical Trial Update: Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function [Phase 1]
Phase 1 trial of sorafenib in patients with metastatic or unresectable solid tumors, multiple myeloma, or non-Hodgkin lymphomas; the study h…
-
CLINICAL_TRIALS trial_result · 2013-01-07Clinical Trial Update: Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating rituximab in combination with oblimersen for follicular lymphoma across stages II–IV has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-07Clinical Trial Update: Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating thalidomide in relapsed or refractory non-Hodgkin lymphoma has completed enrollment. The study included patients wi…
-
CLINICAL_TRIALS trial_result · 2012-11-09Clinical Trial Update: Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
This clinical trial evaluated non-myeloablative allogeneic stem cell transplantation with matched unrelated donors across several hematologi…
-
CLINICAL_TRIALS trial_result · 2012-11-01Clinical Trial Update: Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab [Phase 2]
Phase 2 study comparing Velcade (bortezomib) with fludarabine versus rituximab with fludarabine in follicular lymphoma patients previously t…
-
CLINICAL_TRIALS trial_result · 2012-10-19Clinical Trial Update: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma [Phase 1, Phase 2]
This clinical trial update reports on MDX-010 (ipilimumab) in treating recurrent or refractory lymphoma across multiple subtypes, with the s…
-
CLINICAL_TRIALS trial_result · 2012-09-17Clinical Trial Update: Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) [Phase 2, Phase 3]
Clinical trial evaluating autologous or donor stem cell transplantation for recurrent follicular lymphoma (grades 1-3); study terminated wit…
-
CLINICAL_TRIALS trial_result · 2012-09-05Clinical Trial Update: 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating 131I-rituximab for relapsed or refractory follicular lymphoma or mantle cell lymphoma is reported; curre…